微小RNA-326通过靶向特异性蛋白1逆转人肺腺癌细胞的化疗耐药性。

miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1.

作者信息

Li Jipeng, Li Shanfeng, Chen Zhe, Wang Jianhua, Chen Ying, Xu Zhengyang, Jin Mingwei, Yu Wanjun

机构信息

Department of Central Laboratory, Yinzhou People's Hospital, Ningbo, 315040, China.

Department of Medical Oncology, Yinzhou People's Hospital, Ningbo, 315040, China.

出版信息

Tumour Biol. 2016 Oct;37(10):13287-13294. doi: 10.1007/s13277-016-5244-2. Epub 2016 Jul 26.

Abstract

Cisplatin resistance is a major obstacle in the treatment of lung adenocarcinoma (LAD), and its mechanism has not been fully elucidated. Here, we report that miR-326 is downregulated in cisplatin-resistant A549/CDDP cells compared with parental A549 cells. Overexpression of miR-326 reversed cisplatin chemoresistance of LAD cells in vitro and in vivo. Moreover, we identified the specificity protein 1 (SP1) gene as a novel direct target of miR-326. Knockdown of SP1 revealed similar effects as that of ectopic miR-326 expression. Decreased miR-326 expression was also detected in tumor tissues sampled from LAD patients treated with cisplatin-based chemotherapy and was proved to be correlated with high expression of SP1 and decreased sensitivity to cisplatin. Furthermore, we show that the long noncoding RNA HOTAIR repression reverses chemoresistance of LAD cells partially through modulation of miR-326/SP1 pathway. In summary, we unveil a branch of the HOTAIR/miR-326/SP1 pathway that regulates chemoresistance of LAD cells.

摘要

顺铂耐药是肺腺癌(LAD)治疗中的主要障碍,其机制尚未完全阐明。在此,我们报告,与亲代A549细胞相比,miR-326在顺铂耐药的A549/CDDP细胞中表达下调。miR-326的过表达在体外和体内均逆转了LAD细胞的顺铂化疗耐药性。此外,我们确定特异性蛋白1(SP1)基因是miR-326的一个新的直接靶点。敲低SP1显示出与异位表达miR-326类似的效果。在用基于顺铂的化疗治疗的LAD患者的肿瘤组织中也检测到miR-326表达降低,并且证明其与SP1的高表达和顺铂敏感性降低相关。此外,我们表明长链非编码RNA HOTAIR的抑制部分通过调节miR-326/SP1途径逆转LAD细胞的化疗耐药性。总之,我们揭示了HOTAIR/miR-326/SP1途径的一个分支,该分支调节LAD细胞的化疗耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索